



# Nerve Eze

Bioavailable PEA and ALA  
for Healthy Nerve Function\*

Nerve Eze contains two of the most potent ingredients to promote healthy nerve function: PEA and ALA.\* Together they promote healthy functioning of the body's endocannabinoid system to support nerve function, stress response, relaxation, and healthy immunity.\*

Using Levagen®+ PEA in Nerve Eze supports increased functionality and bioavailability.\* Levagen®+ has undergone human clinical studies demonstrating its safety and effectiveness in enhancing absorption of PEA over standard formulas.\*<sup>1,2,3</sup>

## How Nerve Eze Works

PEA is a bioactive lipid that plays a key role in the endocannabinoid system (ECS) responsible for promoting balanced systems, including the central nervous system and the peripheral nervous system.\*<sup>4</sup> The ECS helps promote relaxation and healthy nerve function.\*

PEA is produced naturally in every cell of the body in biological response to inflammatory markers. Supplementation with PEA helps to promote healthy nerve function by supporting healthy levels of mast cells and glial cells during stress response.\*<sup>4,5,6</sup> PEA promotes healthy nerve function, promotes comfort, and may improve quality of life.\*


Nerve Eze adds alpha-lipoic acid (ALA) to the PEA formulation to further support healthy stress response.\*<sup>7,8</sup> ALA has multiple antioxidant properties and supports healthy glutathione levels in the body's cells.\*<sup>9</sup> Clinical studies show PEA and ALA work together to promote healthy nerve function and stress response.\*<sup>7,8</sup>

An added benefit of using bioavailable Levagen®+ in the Nerve Eze formula is its ability to promote restful sleep and relaxation.\*<sup>10,11,12</sup> PEA has a calming effect on neurological pathways, which ultimately influences immunity, balanced moods, and quality of life.\*<sup>10,11,12</sup>

## Nerve Eze Supplementation

The ingredients in Nerve Eze are congruous with what research suggests to be effective and safe, particularly for promoting healthy nerve function.\* Clinical evidence and research cited herein show that the ingredients in Nerve Eze may:

- Promote healthy nerve function with the enhanced absorption of PEA as bioavailable Levagen®+\*
- Promote healthy functioning of the endocannabinoid system\*
- Support healthy stress response\*
- Support restful sleep and relaxation from PEA's calming effects on neurological pathways\*
- Support healthy immune response\*
- Support balanced moods and neurological health\*
- Promote positive measures of quality of life\*



Form: 60 Capsules

Serving Size: 1 Capsule

Ingredients	Amount	%DV
Palmitoylethanolamide (PEA) (Levagen®+)	300 mg	*
Alpha Lipoic Acid (ALA)	150 mg	*

### Other Ingredients:

Hypromellose, microcrystalline cellulose, vegetable magnesium stearate, silica.

Levagen®+ is a registered trademark of Gencor™.

### Directions:

Take one capsule twice daily or as directed by your healthcare practitioner.

**Caution:** If you are pregnant, nursing, or taking medication, consult your healthcare practitioner before use. Keep out of reach of children.



GLUTEN-FREE



DAIRY-FREE



VEGETARIAN



NON-GMO



PRODUCED IN A  
cGMP FACILITY

\* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## References:

1. Briskey D et al. *A parallel, double-blind, bioavailability study to measure uptake of PEA over a 24-hour period*. Retrieved from <http://www.pharmako.com.au/lipisperse.html>
2. Steels E et al. *Inflammopharmacology*. 2019;27:475-485.
3. Petrosino S et al. *Br J Pharmacol*. 2015;173(7).
4. Paladini A et al. *Pain Physician*. 2016;19(2):11-24.
5. Hesselink JMK. *J Pain Relief*. 2015;8:729-734.
6. Alhouyayek M et al. *Drug Discov Today*. 2014;19(10):1632-1639.
7. Maddaloni E et al. *Diabetes*. 2018;67(1S).
8. Hesselink JMK. *J Pain Relief*. 2015;4(6).
9. Vallianou N et al. *Rev Diabet Stud*. 2009;6(4):230-236.
10. Murillo-Rodriguez E. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;1(32):1420-1427.
11. Vaughn LK et al. *Br J Pharmacol*. 2010;160(3):530-543.
12. Evangelista M et al. *CNS Neurol Disord Drug Targets*. 2018;17(4):291-298.